United States: Patent Term Extension For Drugs Not Limited To New Chemical Entities

Last Updated: June 14 2017
Article by Nicole N. Stakleff and Kyle A. Dolinsky

PTE affords a patent owner up to five additional years on a patent that covers a drug, biologic or class III medical device.

Patent term extension is a valuable tool that drug manufacturers should consider, even when their products are not new entities. Recent decisions from the U.S. Patent and Trademark Office, coupled with various court decisions, have granted patent term extensions (PTEs) for certain pharmaceuticals that do not qualify as new chemical entities (NCEs). The USPTO, however, has been inconsistent in determining eligibility. Among other requirements, to be eligible for PTE, a drug product must be the first permitted commercial marketing for which there was a regulatory review period. The "first permitted commercial marketing of the product" is not equivalent to the FDA's classifying the drug as an NCE. Although NCEs are eligible for PTE, manufacturers should note that there are other circumstances under which a non-NCE may still obtain PTE:

  • New esters or salts of previously approved acids or bases are eligible for PTE.
  • Combination drug products may be eligible for PTE.
  • Combination drug-device products may be eligible for PTE.

Overview of PTE

PTE affords a patent owner up to five additional years on a patent that covers a drug, biologic or class III medical device.1 Generally, to be eligible, the drug product must have been subject to regulatory review before its commercial marketing, and the drug product's approval must be the first approval of the drug by the FDA. The statute defines a "product," in part, as a human drug product, which is "the active ingredient of a new drug . . . including any salt or ester of the active ingredient, as a single entry or in combination with another active ingredient."2

In evaluating a drug's PTE eligibility, the "product" may be the "active ingredient," and not the entire composition of the drug product, based on the statute's plain language.3 The Federal Circuit has remarked that PTEs were intended to be limited to NCEs — and not new uses and new doses of drugs already approved for commercial marketing4 — but the definition of NCE has been expanding.5 Even so, not all companies are seeking approval of an NCE. If they are not seeking NCE approval, are their products still eligible for PTE?

NCEs and New Esters or Salts

An NCE is a drug that contains "no active moiety that has been approved by FDA in any other" new drug application.6 An active moiety is defined as "the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt (including a salt with hydrogen or coordination bonds), or other noncovalent derivative (such as a complex, chelate, or clathrate) of the molecule, responsible for the physiological or pharmacological action of the drug substance."7

In contrast, the PTE statute defines a drug product as "the active ingredient," including any salt or ester. The active ingredient of a drug product is the compound that is actually present in the drug (that gets administered) for which FDA approval was obtained.8 If a product contains a new salt or ester of a previously approved acid, it may be eligible for PTE.9 Similarly, if a product contains a new salt or ester of a previously approved salt or ester, it may be eligible for PTE.

The USPTO takes a different position. It says that if a product contains the acid of a previously approved salt or ester, it is not eligible for PTE, despite the fact that the compound present in the drug that gets administered is different.10 In March 2017, the USPTO issued a decision denying PTE for buprenorphine because the FDA had previously approved a salt of buprenorphine (buprenorphine hydrochloride).11 The USPTO denied PTE for buprenorphine, reasoning that the active ingredient buprenorphine was not the first commercial marketing of buprenorphine or a salt or ester of buprenorphine (since buprenorphine hydrochloride was previously approved) and relied on the decisions in Glaxo v. Quigg, 706 F. Supp. 1224 (E.D. Va. 1989), and Hoescht.

Combination Drug Products

For combination drug products, including fixed-dose combination products, PTE eligibility depends on whether at least one ingredient in the combination product would otherwise be eligible for PTE had it been developed as a monotherapy. In a combination product, if at least one ingredient is an NCE or is a new ester or salt of a previously approved acid, then the combination product will be eligible for PTE.12 If none of the ingredients of the combination product falls into that category, then the combination product will not be eligible, despite the fact that the particular combination of drugs has never been approved before in that combination.

Combination Drug-Device Products

The FDA will review drug-device combination products as either a drug or a medical device for approval purposes. However, for purposes of classifying a product under the Hatch-Waxman Act, "it makes no difference whether the FDA reviews a product as a device, as a drug, as a biological product, or as a unicorn." This is because 35 U.S.C. § 156 enables a drug-device combination product to be classified as either a drug or a medical device for determining PTE eligibility.13 Similar to combination drug products, if either the drug or the device would otherwise be eligible for PTE, the drug-device combination will be eligible for PTE.

Companies developing a new drug product, even if it is not an NCE, should consult with both patent and regulatory counsel to consider whether their product may be eligible for PTE and explore ways to increase the likelihood of obtaining and maximizing PTE.

This article is the first of a five-part series on PTE. Keep an eye on pepperlaw.com for more guidance on how to obtain and maximize PTE for your products.


1 See 35 U.S.C. § 156.

2 35 U.S.C. § 156(f).

3 See Fisons plc v. Quigg, 876 F.2d 99, 101 (Fed. Cir. 1989) (affirming the rejection of PTE for an innovative use or dosage form of cromolyn sodium, which had previously approved by the FDA in inhalation capsule form).

4 Id.

5 See Nemlekar, et al., "FDA Is Evolving on Qualifications for 'New Chemical Entity,'" Law360 (Sept. 7, 2016), https://www.law360.com/articles/836524/fda-is-evolving-on-qualifications-for-new-chemical-entity-.

6 21 C.F.R. § 314.108.

7 21 C.F.R. § 314.103.

8 See PhotoCure Asa v. Kappos, 603 F.3d. 1372, 1375-76 (Fed. Cir. 2010) (holding that the drug product with the active ingredient MAL hydrochloride was eligible for PTE, even though MAL is the methyl ester of ALA and ALA hydrochloride had been previously approved by the FDA); see also Hoechst-Roussel Pharms., Inc. v. Lehman, 109 F.3d 756, 759 n.3 (Fed. Cir. 1997); Glaxo Operations UK Ltd. v. Quigg, 894 F.2d 392, 393-95 (Fed. Cir. 1990).

9 See Glaxo Operations UK Ltd., 894 F.2d 392 (holding that cefuroxime axetil [an ester of cefuroxime] was a new product and eligible for PTE, despite the prior FDA approval of cefuroxime).

10 See http://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance

11 See USPTO Notice of Determination of Ineligibility for Reissue Patent No. 41,571 (Mar. 2, 2017). The USPTO further reasoned that the decision in PhotoCure is also supported, but cautioned that PhotoCure did not provide additional criteria to confer eligibility — for example, that a drug was required to undergo full FDA review or has different pharmacological activities.

12 See Arnold P'ship v. Dudas, 362 F.3d 1338 (Fed. Cir. 2004) (holding that the term of patent directed to combination of hydrocodone and ibuprofen for pain relief could not be extended under § 156, since both components have been available as separate drugs, even though the FDA evaluates the combination of drugs as a whole — not the individual active ingredients — when determining their safety and efficacy). "

13 See Angiotech Pharms. Inc. v. Lee, 191 F. Supp. 3d 509, 524-25 (E.D. Va. 2016) ("When the FDA determines a combination product's primary mode of action for purposes of FDCA review, the FDA is not identifying the nature of the product itself.").

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions